Your Challenges.

Your Challenges.

  • Accelerating R&D

    Embracing in-silico methods, fuelling collaboration and making efficient evidence-based decisions.

  • Minimising Risk

    Having confidence in decisions, mitigating environmental risks and demonstrating compliance.

  • Maximising Value

    Retaining IP, accessibility and promoting and facilitating re-use.

Our Offerings.

Simomics Reason

Represent complex arguments, safety cases and rationale in a transparent and simple way with our goal structuring notation (GSN) diagramming tool.

Virtual Labs

Explore and utilise data and in-silico models to inform and accelerate decision making in a bespoke cloud based virtual laboratory.


Integrate data from multiple sources and owners with machine learning to classify and protect sensitive data.

Bespoke Development

Bespoke model and software optimisation projects and cloud based solutions utilising Simomics novel technology.


Hands on support and consultancy for modelling, simulation and development activities from the Simomics team.

About Simomics.

Based in York since 2014, Simomics is an ethics-led software technology SME, driven by a strong mission and purpose to promote corporate environmental responsibility, and the replacement, reduction, and refinement of the use of animals for scientific purposes through in-silico modelling.

We develop technologies to explore, communicate and maximise the value from computer based (in-silico) models to accelerate and de-risk R&D and support key environmental protection initiatives.

Combining world leading expertise in life science, software engineering and data science, we work with global clients and partners in the pharmaceutical, agrochemical, personal care and environmental industries.

£ 0 +

Has been awarded in research grant funding to Simomics.

0 +

Citations have been made from our academic founders’ publications in the fields of computation & immunology.

We help the biggest and brightest have confidence in decisions,
and the data, models and AI behind them.

We are developing the digital assessment system at the heart of the PREMIER IMI2 project for the prioritization and risk evaluation of Active Pharmaceutical Ingredients in the environment, in partnership with AstraZeneca, GlaxoSmithKline, Bayer, Bristol-Myers Squibb, Novartis, Sanofi, Eli Lilly, Merck and others.

A world-leading personal care company has been using our Reason software since 2016 to assist with their toxicology risk assessments. We continue to be engaged to explore integration opportunities with their environmental risk assessment work.

We are working with one of the world’s largest biotech companies to re-implement a complex mathematical model for the trafficking of CAR T-cells, converting C and Python code into MATLAB. Our Simomics Evidence technology makes the code more accessible and reusable, exposing the provenance of data, evidence and assumptions.

Insights and updates
from the Simomics team.

Introduction to the PREMIER Project

Introduction to the PREMIER Project Simomics is delighted to announce that the Innovative Medicines Initiative (IMI), a partnership funded by the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA), has officially launched the project  “Prioritisation and Risk Evaluation of Medicines in the EnviRonment”…

We'd love to hear from you.

+44 (0)7377 093 282

Simomics Ltd, Blake House, 18 Blake Street, York, YO1 8QG

Scroll to Top